Stool Alpha-1 Antitrypsin Diagnostics: Introduction
- Alpha-1 antitrypsin (AAT) is a protein produced in the liver that circulates through blood. The alpha-1 antitrypsin protein primarily protects the body’s own tissues and cells from being damaged by activated immune response to foreign infection, autoimmune disorder, and other foreign particles.
- AAT protein is crucial in maintaining regulatory and anti-inflammatory response during the immune response to foreign particles. Thus, it protects healthy cells and tissues. This protective characteristic of AAT is being considered a key biomarker for the diagnosis of various inflammatory, gastrointestinal, and immunological disorders.
- Various gastrointestinal and inflammatory disorders show abnormal levels of AAT in stool sample. AAT is commonly present in high quantities in inflammatory bowel diseases, celiac diseases, necrotic enterocolitis, colon cancer, Whipple disease, colon polyps, and systemic lupus erythematosus.
- The stool AAT diagnostic test is non-invasive. It is commonly performed using ELISA technology. It is used in conjunction with diagnostic test as a complementary test.
Stool Alpha-1 Antitrypsin Diagnostics Market: Key Drivers
- High prevalence and rise in incidence rate of gastrointestinal disorders such as inflammatory bowel disease and celiac disease across the globe is one of the key factors driving the stool alpha-1 antitrypsin diagnostics market
- According to a research article published in the Lancet Journal in 2017, there were more than 6.7 million people afflicted with the inflammatory bowel disease across the globe in the year
- Around 2.5 million to 3 million people in Europe are affected by the inflammatory bowel disease per year. Highest incidence and prevalence of the inflammatory bowel disease is observed in Scandinavia and the U.K. Incidence of Crohn’s disease in Europe ranges from 0.5 to 10.6 cases per 100,000 people per year, while that of ulcerative colitis ranges from 0.9 to 24.3 per 100,000 per year.
- Low cost of the test, ease of conducting the test, non-invasive nature of the test, and high clinical importance of stool alpha-1 antitrypsin are estimated to boost the market during the forecast period
Inflammatory Bowel Disease Segment to be Highly Attractive
- In terms of indication, the global market can be segmented into inflammatory bowel disease, necrotic enterocolitis, celiac disease, systemic lupus erythematosus, and others. The inflammatory bowel disease segment is estimated to dominate the market during the forecast period.
Diagnostic laboratories to be Highly Attractive Segment
- Based on end-user, the global stool alpha-1 antitrypsin diagnostics market can be classified into hospitals, diagnostic laboratories, and academic and research institutes. The diagnostic laboratories segment is projected to dominate the global market during the forecast period.
- Presence of large numbers of diagnostic laboratories, easy availability and accessibility of test at these centers, and low cost are factors that are likely to drive the diagnostic laboratories segment in the near future
Asia Pacific Stool Alpha-1 Antitrypsin Diagnostics Market to Expand Rapidly
- In terms of region, the global stool alpha-1 antitrypsin diagnostics market can be split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America is likely to dominate the global market during the forecast period. High prevalence of inflammatory bowel disease and necrotic enterocolitis and growth in aging population are factors expected to boost the market in the region during the forecast period.
- The stool alpha-1 antitrypsin diagnostics market in Asia Pacific is anticipated to expand at a fast-paced CAGR during the forecast period. Rapid growth of the market in the region can be ascribed to rise in incidence rate of inflammatory bowel disease and necrotic enterocolitis in densely populated countries such as India and China, and improvement of health care infrastructure in the region.
- High growth rate of the health care industry, easy access to health care facilities, and increase in investments in health care by leading players in Asia Pacific are expected to fuel the market in the region in the near future
Key Players Operating in Global Stool Alpha-1 Antitrypsin Diagnostics Market
The global stool alpha-1 antitrypsin diagnostics market is fragmented, with large number of global players holding majority share. Prominent players operating in the global stool alpha-1 antitrypsin market include:
- ORGENTEC Diagnostika GmbH
- R-Biopharm AG
- Tecan Trading AG (IBL International GmbH)
- Immundiagnostik AG
- BioVendor Group
- LifeSpan BioSciences, Inc.
- RayBiotech, Inc.
- Eagle Bioscience, Inc.
Global Stool Alpha-1 Antitrypsin Diagnostics Market: Research Scope
Global Stool Alpha-1 Antitrypsin Diagnostics Market, by Indication
- Inflammatory Bowel Diseases
- Necrotic Enterocolitis
- Celiac Disease
- Systemic Lupus Erythematosus
- Others
Global Stool Alpha-1 Antitrypsin Diagnostics Market, by Distribution Channel
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
Global Stool Alpha-1 Antitrypsin Diagnostics Market, by Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Interested in this report?
Get a FREE Brochure now!
